載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.625
−US$0.025 · -1.52%
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
一般交易時段
US$1.625
−US$0.025 · -1.52%
盤中時間採用ET。市場資料可能有所延遲。
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
日內區間
目前US$1.625
52週區間
目前US$1.625
盤中時間採用ET。市場資料可能有所延遲。
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
日內區間
目前US$1.625
52週區間
目前US$1.625
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4980.3萬 USD | 3108.1萬 USD | 120.4萬 USD | 13.9萬 USD | 29.8萬 USD |
| 銷貨成本 | 27.4萬 USD | 61.6萬 USD | 5897.2萬 USD | 5251.6萬 USD | 5504.6萬 USD |
| 毛利 | 4952.9萬 USD | 3046.5萬 USD | −5776.8萬 USD | −5237.7萬 USD | −5474.8萬 USD |
| 研究與開發 | 6112.1萬 USD | 8448萬 USD | 5888.7萬 USD | 5281.6萬 USD | 5504.6萬 USD |
| 銷售、一般及管理費用 | 3731.9萬 USD | 1.32億 USD | — | — | — |
| 營業費用 | 9844萬 USD | 2.28億 USD | 1.14億 USD | 4838.3萬 USD | 3234.2萬 USD |
| 利息收入 | 690.9萬 USD | 1229.3萬 USD | 773.2萬 USD | 159.6萬 USD | 13.4萬 USD |
| 利息支出 | 833.9萬 USD | 1557.9萬 USD | 1310.1萬 USD | 278萬 USD | 80.2萬 USD |
| 折舊和攤銷 | 62.1萬 USD | 53.4萬 USD | 55.4萬 USD | 42.7萬 USD | 29.2萬 USD |
| 營業利益 | −4891.1萬 USD | −1.97億 USD | −1.72億 USD | −1.01億 USD | −8709萬 USD |
| 淨利 | −5034.1萬 USD | −2億 USD | −1.77億 USD | −1.02億 USD | −8775.8萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1593.82萬0.00%2.3兆 USD0.03%US$380.8-0.20%
iShares Russell 2000 ETFIWM965.88萬0.01%787.4億 USD0.19%US$276.23-0.60%
Vanguard Extended Market ETFVXF590.81萬0.01%954億 USD0.05%US$231.88-0.70%
iShares Russell 2000 Growth ETFIWO347.79萬0.03%139.17億 USD0.24%US$350.82-0.82%
State Street SPDR S&P Pharmaceuticals ETFXPH339.27萬0.74%4.69億 USD0.35%US$63.36-1.02%
Vanguard Russell 2000 ETFVTWO322.24萬0.02%180億 USD0.06%US$111.58-0.62%
Schwab U.S. Small-Cap ETFSCHA184萬0.01%217.13億 USD0.03%US$32.47-0.58%
Vanguard Health Care ETFVHT145.19萬0.01%220億 USD0.09%US$317.22-1.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
